DEVELOPMENT OF PERSONALIZED ANTICANCER THERAPY BY INHALABLE DRY POWDER BASED ON NONINVASIVE LUNG DEPOSITION MONITORING
| Project/Area Number |
22790051
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Single-year Grants |
|---|
| Research Field |
Physical pharmacy
|
|---|
| Research Institution | Meijo University |
|---|
Principal Investigator |
|
|---|
| Research Collaborator |
OKAMOTO Hirokazu 名城大学, 薬学部, 教授 (00308941)
|
|---|
| Project Period (FY) |
2010 – 2011
|
| Project Status |
Completed (Fiscal Year 2011)
|
| Budget Amount *help |
¥4,290,000 (Direct Cost: ¥3,300,000、Indirect Cost: ¥990,000)
Fiscal Year 2011: ¥650,000 (Direct Cost: ¥500,000、Indirect Cost: ¥150,000)
Fiscal Year 2010: ¥3,640,000 (Direct Cost: ¥2,800,000、Indirect Cost: ¥840,000)
|
|---|
| Keywords | 粉末吸入製剤 / 近赤外蛍光ラベル / in vivoイメージング / 肺癌治療 / 肺内送達 / テーラーメイド医療 / 噴霧急速凍結乾燥法 / 多孔性微粒子 |
|---|
| Research Abstract |
In this study, a novel inhalable dry anticancer powder containing doxorubicin(DOX) was prepared, labeled with a near-infrared fluorescent probe(indocyanin green ; ICG) for easily and noninvasively evaluating lung deposition. Following pulmonary administration of the powder into mice, it was suggested that the in-vivo fluorescence intensity in the lungs derived from ICG was significantly correlated not only with the ex-vivo fluorescence intensity in the excised lungs derived from DOX, but also with the anticancer effect in the lungs.
|
Report
(3 results)
Research Products
(6 results)
